BioCentury | Oct 21, 2002
Clinical News

Coenzyme Q10: Phase II

...from placebo. The study was funded by the National Institute of Neurological Disorders and Stroke. Vitaline Corp....
BioCentury | Aug 20, 2001
Clinical News

Coenzyme Q10: Phase III

...a trend toward improving the degree of chorea. Remacemide is an NMDA glutamate receptor blocker. Vitaline Corp....
Items per page:
1 - 2 of 2
BioCentury | Oct 21, 2002
Clinical News

Coenzyme Q10: Phase II

...from placebo. The study was funded by the National Institute of Neurological Disorders and Stroke. Vitaline Corp....
BioCentury | Aug 20, 2001
Clinical News

Coenzyme Q10: Phase III

...a trend toward improving the degree of chorea. Remacemide is an NMDA glutamate receptor blocker. Vitaline Corp....
Items per page:
1 - 2 of 2